US FDA calls Wockhardt efforts to fix Wrexham plant 'inadequate'

By Gareth Macdonald contact

- Last updated on GMT

Google maps
Google maps

Related tags: Current good manufacturing, Warning letter, Food and drug administration

Efforts by Wockhardt to fix violations at drug plant in Wrexham, Wales are inadequate according to the US FDA which detailed its concerns in a warning letter this week.

The warning letter​, dated November 16, discusses the Indian drug firm’s response to an inspection last October when agency staff detected a number of violations of current good manufacturing practice (cGMP) at the facility.

The Food and Drug Administration (FDA) said Wockhardt’s response to the inspection – which it received late last year - was ‘inadequate’ and advised it to hire a consultant to help it bring the facility up to code.

Wockhardt acquired the facility in 2003​ when it bought CP Pharmaceuticals.

Just last week the firm said it planned to build a sterile manufacturing and drug testing facility at its site in a $12.4m that will create 50 jobs

The firm did not respond to a request for comment.

Related news

Show more

Related products

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us

Products

View more

Webinars